Overview

TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This double-blind, randomized controlled trial evaluates moxifloxacin versus isoniazid in daily treatment during the first two months of treatment with rifampin, pyrazinamide and ethambutol for sputum smear-positive pulmonary tuberculosis.
Phase:
Phase 2
Details
Lead Sponsor:
Centers for Disease Control and Prevention
Collaborators:
Bayer
Global Alliance for TB Drug Development
Treatments:
Ethambutol
Fluoroquinolones
Isoniazid
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Pyrazinamide
Rifampin